Delivery Order SPE2DB20D3505-SPE2DB24FT5J0
- Not listed
- This federal contract award is for the delivery of Emgality 120 mg/ml injectable medication to the Defense Logistics Agency (DLA). The $1,669.08 firm fixed-price delivery order was awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 17, 2023. The contract has an ultimate completion date of January 18, 2023 and was not set aside for any specific business type. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc.,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Emgality 120 mg/mL injectable medication. The $1,671.20 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities...
- This federal contract award is for the delivery of Emgality 120 mg/ml injectable medication to the Defense Logistics Agency (DLA) Troop Support Medical. The $1,002.72 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, on September 26, 2024 with a completion date of September 27, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that AmerisourceBergen holds with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of Emgality 120 mg/mL injectable medication. The $2,658.47 firm fixed-price delivery order is a part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. (doing business as Amerisourcebergen) holds with the DLA Troop Support Medical. This IDC serves as the...
- This federal contract award is for the delivery of Emgality 300 mg (100 mg x 3 syringes) to the Defense Logistics Agency (DLA), a component of the Department of Defense. The $4,586.63 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on September 24, 2021, with a completion date of September 27, 2021. The contract has no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of the parent...
- This federal contract award is for the provision of the pharmaceutical drug Emgality 300 mg (100 mg x 3 syringes) to the Defense Logistics Agency (DLA). The $3,095.68 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc. This contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,787.20 firm-fixed-price delivery order covers the supply of the prescription drug Emgality 120 mg/ml injectable. The award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Cencora, Inc. (doing business as Amerisourcebergen) holds with the DLA Troop Support Medical, which enables the...
- The federal contract award, with ID SPE2DB20D2002|SPE2DB24FL86U, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,131.78 firm fixed-price delivery order covers the supply of Emgality 120 mg/ml injectable medication. The contract has a completion date of September 12, 2024. Amerisourcebergen, a for-profit organization, is the prime contractor for this award, which is not designated as a set-aside. This contract is a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,593.50 Firm Fixed Price Delivery Order covers the supply of Emgality 120 mg/mL injectable medication, with a period of performance through December 4, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract, valued at up to $3,212.48, is for the delivery of Emgality 120 mg/ml injectable medication. The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB24FT5J0Delivery Order
This federal contract award is for the delivery of Emgality, a 120 mg/mL injectable medication, to the Defense Logistics Agency (DLA) by the prime contractor, Amerisourcebergen Drug Corp. The $1,173.48 firm-fixed-price delivery order contract has a completion date of January 2, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is registered in the System for Award Management (SAM.gov). The contract is not designated as a set-aside and was awarded through full and open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 12/29/23 |